Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 3/20 | 0.73 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.73 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27276869 | 1.00 | OPRM1 (0.73) | OPRM1OPRD1OPRK1 | |
| SCHEMBL5899132 | 1.00 | OPRM1 (0.73) | OPRM1OPRD1OPRK1 | |
| Hydrochloric Acid SCHEMBL8351442 | 0.99 | OPRM1 (0.72) | OPRM1OPRD1OPRK1 | |
| Hydrochloric Acid SCHEMBL9262175 | 0.99 | OPRM1 (0.72) | OPRM1OPRD1OPRK1 | |
| Hydrochloric Acid SCHEMBL9262170 | 0.99 | OPRM1 (0.72) | OPRM1OPRD1OPRK1 | |
| Hydrochloric Acid SCHEMBL8351444 | 0.99 | OPRM1 (0.72) | OPRM1OPRD1OPRK1 | |
| SCHEMBL27274318 | 0.99 | OPRM1 (0.74) | OPRM1OPRD1OPRK1 | |
| Hydrochloric Acid SCHEMBL9260034 | 0.98 | OPRM1 (0.73) | OPRM1OPRD1OPRK1 | |
| Hydrochloric Acid SCHEMBL9260036 | 0.98 | OPRM1 (0.73) | OPRM1OPRD1OPRK1 | |
| SCHEMBL27276868 | 0.88 | OPRM1 (0.72) | OPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7012083-B2 | Compounds useful in therapy | PFIZER INC. (US) | 2006-03-14 | — | — | US | disclosed |
| US-20050085456-A1 | Compounds useful in therapy | PFIZER, INC. (US) | 2005-04-21 | — | — | US | disclosed |
| US-6812236-B2 | FOR THERAPY OF PRUTIUS | PFIZER INC. | 2004-11-02 | — | — | US | disclosed |
| EP-1072601-B1 | 4-arylpiperidine derivatives for the treatment of pruritus | PFIZER (US) | 2004-09-08 | — | — | EP | disclosed |
| EP-1077940-B1 | 4-PHENYLPIPERIDINES FOR THE TREATMENT OF PRURITIC DERMATOSES | PFIZER (US) | 2004-07-14 | — | — | EP | disclosed |
| US-6750231-B2 | SKIN DISORDERS; GASTROINTESTINAL DISORDERS | PFIZER INC | 2004-06-15 | — | — | US | disclosed |
| US-6610711-B2 | 4-phenylpiperidines for the treatment of pruritic dermatoses | PFIZER INC. | 2003-08-26 | — | — | US | disclosed |
| US-20030078282-A1 | Novel 4-phenylpiperidines for the treatment of pruritic dermatoses | PFIZER INC. | 2003-04-24 | — | — | US | disclosed |
| US-20030004340-A1 | New 4-arylpiperidine derivatives for the treatment of pruritus | GIBSON STEPHEN PAUL (GB) | 2003-01-02 | — | — | US | disclosed |
| US-6479516-B1 | TREATMENT OF PRURITIC DERMATOSES INCLUDING ALLERGIC DERMATITIS AND ATOPY IN ANIMALS AND HUMANS | PFIZER INC | 2002-11-12 | — | — | US | disclosed |
| EP-1072594-A2 | 4-arylpiperidine derivatives for the treatment of pruritus | PFIZER INC. (US) | 2001-01-31 | — | — | EP | disclosed |
| EP-1072596-A2 | 4-arylpiperidine derivatives for the treatment of pruritus | PFIZER INC. (US) | 2001-01-31 | — | — | EP | disclosed |
| EP-1072601-A2 | 4-arylpiperidine derivatives for the treatment of pruritus | PFIZER INC. (US) | 2001-01-31 | — | — | EP | disclosed |
| EP-1072592-A2 | 4-arylpiperidine derivatives for the treatment of pruritus | PFIZER INC. (US) | 2001-01-31 | — | — | EP | disclosed |
| EP-1055668-A1 | New 4-arylpiperidine derivatives for the treatment of pruritus | PFIZER INC. (US) | 2000-11-29 | — | — | EP | disclosed |
| WO-1999059971-A1 | NOVEL 4-PHENYLPIPERIDINES FOR THE TREATMENT OF PRURITIC DERMATOSES | PFIZER INC. (US) | 1999-11-25 | — | — | WO | disclosed |
| US-5972962-A | Treatment of pruritus | PFIZER INC. (US) | 1999-10-26 | — | — | US | disclosed |
| EP-0938898-A2 | Treatment of pruritus | Pfizer Limited (GB) | 1999-09-01 | — | — | EP | disclosed |
| CN-1017992-B | PROCESS FOR PREPARING PIPERIDINE OPIOID ANTAGONISTS | LILLY CO ELI (US) | 1992-08-26 | — | — | CN | disclosed |
| CN-88102191-A | Process for preparing piperidine opioid antagonists | — | 1988-11-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085456-A1 | Compounds useful in therapy | OPRL1, OPRD1, BDKRB1 | OPRM1 5/4885OPRD1 2/4885OPRK1 9/4885 |
| US-20030004340-A1 | New 4-arylpiperidine derivatives for the treatment of pruritus | HRH2, HRH4, HRH1 | OPRM1 9/4885OPRD1 4/4885OPRK1 11/4885 |
| US-20030078282-A1 | Novel 4-phenylpiperidines for the treatment of pruritic dermatoses | HRH2, HRH4, HRH1 | OPRM1 409/4885OPRD1 102/4885OPRK1 144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.